Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  St. Jude Medical, Inc.    STJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

St. Jude Medical, Inc. : StockCall Scrutinizes STJ, HOLX, NAVB, EW, and RMD

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/17/2013 | 02:35pm CET

StockCall.com Provides Stock Research on St. Jude Medical Inc., Hologic Inc., Navidea Biopharmaceuticals Inc., Edwards Lifesciences Corp., and ResMed Inc.

New York City, New York -- (May 17, 2013)

The Affordable Care Act (ACA), which is the biggest overhaul of the healthcare industry in decades, has generally been welcomed by the healthcare industry. The industry believes that the increase in the number of insured individuals due to the ACA will ultimately benefit it. However, medical appliances & equipment makers have been the most vocal critics of the reform. This is because medical appliances & equipment are required to pay a 2.3% tax on gross U.S. sales of medical devices. The industry believes that this will result in higher costs and hurt innovation. On Thursday, shares of medical appliances & equipment companies ended mostly lower, tracking losses in the broad market. Among the major movers in the sector were St. Jude Medical Inc. (NYSE: STJ), Hologic Inc. (NASDAQ: HOLX), Navidea Biopharmaceuticals Inc. (AMEX: NAVB), Edwards Lifesciences Corp. (NYSE: EW), and ResMed Inc. (NYSE: RMD). StockCall reviewed the medical appliances & equipment industry and chose STJ, HOLX, NAVB, EW, and RMD for its technical coverage. These free reports can be seen for free at

www.stockcall.com/signup

Shares of St. Jude Medical Inc. edged higher on Thursday, touching a 52-week high of $47.14. The stock closed 0.54% higher at $46.82 on above average volume of 3.43 million. St. Jude Medical?s shares have gained more than 3.50% in the last three trading sessions. The stock has seen a series of highs over the past two weeks which is a bullish signal. Despite the challenges facing the industry, shares of STJ have gained more than 30.30% so far in 2013. Download the free research on STJ by signing up now at

www.StockCall.com/STJ051713.pdf

Shares of Hologic Inc. fell in trading yesterday, extending its losses from previous trading sessions. The stock ended the day 1.04% lower at $20.87 on volume of 2.12 million, taking its losses in the last three sessions to more than 2.10%. Year-to-date, shares of HOLX have gained 4.30% as compared to a growth of more than 15.70% for the S&P 500. The stock is currently trading 12.90% below its 52-week high. Shares are currently trading below their 50-day and 200-day moving averages which is a bearish signal. Register for today?s free analysis on HOLX at

www.StockCall.com/HOLX051713.pdf

Navidea Biopharmaceuticals Inc.?s shares fell sharply on Thursday. The stock finished the day 2.49% lower at $2.35 on volume of 607,040. Navidea?s shares are currently trading close to their 52-week low of $2.14. The stock has fallen nearly 17% so far this year even as the broad market has rallied. The company?s shares are currently trading well below their 50-day and 200-day moving averages. Free report on NAVB can be accessed by registering at

www.StockCall.com/NAVB051713.pdf

Shares of Edwards Lifesciences Corp. struggled in trading yesterday. The stock traded between $67.75 and $70.85 before finishing the day 3.56% lower at $68.81 on above average volume of 2 million. Despite the sharp decline on Thursday, Edwards Lifesciences? shares are up nearly 1.90% in the last three trading sessions. The stock had seen a series of highs this week before seeing a pullback yesterday. Shares of the company have fallen nearly 24% so far in 2013.Register withStockCall and download the research on EW for free at

www.StockCall.com/EW051713.pdf

Shares of ResMed Inc. edged lower on Thursday. The stock closed 1.46% lower at $49.80 on volume of 1.05 million which is in-line with the daily average. Despite the pullback, ResMed?s shares are currently trading close to their 52-week high of $51.40. The stock has outperformed the broad market this year, gaining more than 20.20%. Shares of the company are also trading well above their 50-day and 200-day moving averages. Read the full free research on RMD by signing up to StockCall at

www.StockCall.com/RMD051713.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

www.stockcall.com

Contact Person:

William T. Knight

Email: info@stockcall.com

Contact Number: (646) 396-9857 (9:00 am EST ? 01:30 pm EST)


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ST. JUDE MEDICAL, INC.
11/28 Global Radiofrequency Ablation Market - Angiodynamics, Boston Scientific, Cov..
11/24 ST JUDE MEDICAL : Assigned Patent
11/22 ST JUDE MEDICAL : Patent Issued for Method for Loading a Self-Expanding Collapsi..
11/22 ST JUDE MEDICAL : Patent Issued for Methods and Apparatus for Controlling the In..
11/22 ST JUDE MEDICAL : HeartMate 3 LVAS Demonstrated Improved Clinical Outcomes for P..
11/17 ST JUDE MEDICAL : Federal Contracts Awarded to Companies in Minnesota (Nov. 17)
11/17 ST JUDE MEDICAL : Gains CE Mark Approval for MRI Labeling of its Quadra Allure M..
11/17 DEADLINE UPCOMING IN $39.25 MILLION : STJ) Investor Lawsuit
11/17 ABBOTT LABORATORIES (NASDAQ : ABT) Files An 8-K Other Events
11/17 ABBOTT LABORATORIES (NYSE : ABT) Files An 8-K Other Events
More news
Sector news : Medical Devices & Implants
11/22DJMEDTRONIC : Cuts Guidance on Sluggish Revenue
11/22DJMEDTRONIC : Cuts Guidance on Sluggish Revenue -- 2nd Update
11/22DJMEDTRONIC : Cuts Guidance on Sluggish Revenue
11/15 EXCLUSIVE : EU regulators seen clearing $25 billion Abbott, St Jude deal
11/15 Exclusive - EU regulators seen clearing $25 billion Abbott, St Jude deal
More sector news : Medical Devices & Implants
News from SeekingAlpha
11/28 5 Dividends That Make The Difference
11/23 Blackberry Plans To Shake Up Medtech Cybersecurity
11/21 Buffett's Berkshire Flies
11/16 Interim study data confirms benefit of St. Jude's HeartMate 3 LVAS system
11/16 Top Merger Stocks Held By Fund Managers (Mid-Q4 2016 Edition)
Advertisement
Financials ($)
Sales 2016 6 044 M
EBIT 2016 1 510 M
Net income 2016 898 M
Debt 2016 4 713 M
Yield 2016 1,48%
P/E ratio 2016 25,06
P/E ratio 2017 19,87
EV / Sales 2016 4,52x
EV / Sales 2017 4,13x
Capitalization 22 577 M
More Financials
Chart ST. JUDE MEDICAL, INC.
Duration : Period :
St. Jude Medical, Inc. Technical Analysis Chart | STJ | US7908491035 | 4-Traders
Full-screen chart
Technical analysis trends ST. JUDE MEDICAL,...
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 20
Average target price 82,0 $
Spread / Average Target 3,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michael T. Rousseau President, Chief Executive Officer & Director
Daniel J. Starks Executive Chairman
Scott P. Thome Vice President-Global Operations & Supply Chain
Donald J. Zurbay Chief Financial Officer & Vice President
Mark D. Carlson Chief Medical Officer & VP-Global Clinical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ST. JUDE MEDICAL, INC.28.22%22 509
STRYKER CORPORATION22.29%41 845
SMITH & NEPHEW PLC-8.44%12 169
WRIGHT MEDICAL GROUP N..-4.55%2 375
GLAUKOS CORP26.41%1 027
OSSTEM IMPLANT CO LTD--.--%667
More Results